BRPI0716317A2 - Método para reduzir a absorção de fosfato em um individuo animal humano ou não-humano e método para reduzir a absorção de fosfato em um individuo humano - Google Patents

Método para reduzir a absorção de fosfato em um individuo animal humano ou não-humano e método para reduzir a absorção de fosfato em um individuo humano

Info

Publication number
BRPI0716317A2
BRPI0716317A2 BRPI0716317-7A2A BRPI0716317A BRPI0716317A2 BR PI0716317 A2 BRPI0716317 A2 BR PI0716317A2 BR PI0716317 A BRPI0716317 A BR PI0716317A BR PI0716317 A2 BRPI0716317 A2 BR PI0716317A2
Authority
BR
Brazil
Prior art keywords
human
individual
phosphate absorption
reducing phosphate
reducing
Prior art date
Application number
BRPI0716317-7A2A
Other languages
English (en)
Inventor
Mark Cook
Martin Petrovich
Christian Helving
Erica Hellestad
Keith Crawford
Original Assignee
Winsconsin Alumni Res Foundation
Aovatechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winsconsin Alumni Res Foundation, Aovatechnologies Inc filed Critical Winsconsin Alumni Res Foundation
Publication of BRPI0716317A2 publication Critical patent/BRPI0716317A2/pt
Publication of BRPI0716317A8 publication Critical patent/BRPI0716317A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0716317A 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano BRPI0716317A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85455006P 2006-10-26 2006-10-26
PCT/US2007/082244 WO2008051977A2 (en) 2006-10-26 2007-10-23 Methods of reducing phosphate absorption

Publications (2)

Publication Number Publication Date
BRPI0716317A2 true BRPI0716317A2 (pt) 2014-02-25
BRPI0716317A8 BRPI0716317A8 (pt) 2019-02-05

Family

ID=38983491

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0716320-7A2A BRPI0716320A2 (pt) 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano
BRPI0716317A BRPI0716317A8 (pt) 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0716320-7A2A BRPI0716320A2 (pt) 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano

Country Status (8)

Country Link
US (2) US8877198B2 (pt)
EP (2) EP2081963A2 (pt)
JP (3) JP5701504B2 (pt)
CN (2) CN101583627A (pt)
AU (2) AU2007309026B2 (pt)
BR (2) BRPI0716320A2 (pt)
CA (2) CA2667563A1 (pt)
WO (2) WO2008051977A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051980A2 (en) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
CN101583627A (zh) 2006-10-26 2009-11-18 威斯康星大学校友研究基金会 减少磷酸盐吸收的方法
CA2739545C (en) * 2008-10-17 2018-09-25 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225254B1 (en) * 1985-11-25 1994-03-16 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
AU1526995A (en) * 1994-01-13 1995-08-01 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations, The Antibodies specific for d-myo-inositol 1,4,5-trisphosphate
ATE238810T1 (de) * 1994-08-05 2003-05-15 Wisconsin Alumni Res Found Cck-antikörper zur verbesserung der futterverwertung
ES2162658T3 (es) 1996-03-05 2002-01-01 Mitsubishi Chem Corp Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia.
US6180094B1 (en) 1996-07-19 2001-01-30 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CH694588A5 (de) * 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
US6213930B1 (en) * 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7355092B2 (en) * 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
AU2001271880A1 (en) * 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing targeted phosphatase gene disruptions
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
JP4886983B2 (ja) * 2004-12-09 2012-02-29 アサマ化成株式会社 抗体を含有する機能性組成物
WO2008051980A2 (en) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
CN101583627A (zh) * 2006-10-26 2009-11-18 威斯康星大学校友研究基金会 减少磷酸盐吸收的方法

Also Published As

Publication number Publication date
US20100233184A1 (en) 2010-09-16
WO2008067084A2 (en) 2008-06-05
CA2667563A1 (en) 2008-05-02
AU2007325459A1 (en) 2008-06-05
US20100143385A1 (en) 2010-06-10
BRPI0716317A8 (pt) 2019-02-05
CA2667613A1 (en) 2008-06-05
WO2008067084A3 (en) 2008-07-31
AU2007309026A1 (en) 2008-05-02
JP5701504B2 (ja) 2015-04-15
CN101583627A (zh) 2009-11-18
EP2081963A2 (en) 2009-07-29
AU2007309026B2 (en) 2013-09-12
WO2008051977A8 (en) 2009-05-28
WO2008051977A3 (en) 2008-07-03
JP2014237591A (ja) 2014-12-18
EP2076543A2 (en) 2009-07-08
US8877198B2 (en) 2014-11-04
WO2008051977A2 (en) 2008-05-02
BRPI0716320A2 (pt) 2014-02-25
CN101595131A (zh) 2009-12-02
JP2010508281A (ja) 2010-03-18
EP2076543B1 (en) 2016-01-27
JP2010508282A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0914090A2 (pt) sistema de redução e método para reduzir um período de penalidade para um trem de potência distribuida
BRPI0819075A2 (pt) Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
EP2207595A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF ANIMAL TISSUE USING LASER LIGHT
EP2085882A4 (en) MULTI-PROCESSOR SYSTEM, SYSTEM CONFIGURATION METHOD IN MULTI-PROCESSOR SYSTEM, AND PROGRAM THEREOF
GB0719969D0 (en) Substance monitoring and control in human or animal bodies
CL2007002965A1 (es) Metodo y sistema para entregar y ejecutar las mejores practicas en proyectos de desarrollo de yacimiento petrolifero.
BRPI0613893A2 (pt) sistema e método para tratar pele
EP1800120A4 (en) METHODS AND SYSTEMS FOR PROVIDING AN INDIVIDUAL ANIMAL-SPECIFIC ALICAMENT PROGRAM
EP1899908A4 (en) INTEGRATED MODULE FOR REAL-TIME RISK ANALYSIS AND TREATMENT
BRPI0906683A2 (pt) método para medir e caracterizar microvesículas em fluidos corporais humanos
EP2126702A4 (en) ANALYSIS AND SYSTEM MANAGEMENT
EP1979744A4 (en) COMPUTERIZED SYSTEM AND METHOD FOR LAND DEVELOPMENT
BRPI0822095A2 (pt) Método para reduzir o sangramento e/ou hematoma em um paciente
BRPI0908656A2 (pt) ''método para reduzir a corrosão de sensor em artigos absorventes''
DE502007005036D1 (de) Vorrichtung zur energieabsorption
EP2092967A4 (en) GAME SYSTEM AND GAME EXECUTION MANAGEMENT METHOD
BRPI0720604B8 (pt) composição e método para detecção de desmineralização
BRPI0813734A2 (pt) Sistema informatizado de viagem, método em um sistema de viagem e programa de computador
BRPI0915698A2 (pt) método para medir o conteúdo de água em um composto e dispositivo de medição de conteúdo de água
BRPI0911186A2 (pt) trem de rolamento unitário e conjunto de rolamento que o compreende
EP2213243A4 (en) METHOD FOR EVALUATING EFFICACY; DEVICE FOR ASSESSING EFFICACY AND PROGRAM FOR EVALUATING THE EFFECTIVENESS OF A TOPICAL SKIN PREPARATION
EP2092480A4 (en) TRANSACTION SYSTEM AND METHOD
BRPI0815176A2 (pt) Método e sensor para perceber moedas para avaliação
BRPI0918103A2 (pt) "método para o tratamento da dor em um indivíduo"
GB0614218D0 (en) Device and method for altering cardiac activity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]